BioSpace News Archive

Genmab A/S announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY™ as the first and only T-cell engaging bispecific antibody treatment in Japan of adult patients with certain types of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy.

Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application on August 17, 2023, and was accepted for review by the US Food and Drug Administration on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics.

Vapotherm, Inc. announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023.

Passage Bio, Inc. today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET.

Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives.

Delta Development Team is thrilled to announce the successful completion of its oversubscribed Series A round, which was led by major investors UAVC and Desert Angels.

Viridian Therapeutics, Inc. today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.

Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs.

Inovalon today announced that its annual Customer Congress will take place from October 15-17, 2023 in Washington, D.C.